🇦🇺 Australia Country × Condition
non small cell lung cancer Clinical Trials in Australia
Active clinical trials for non small cell lung cancer with research sites in Australia. All data sourced live from ClinicalTrials.gov — updated daily.
Active Trials: 10 // Recruiting: 10 Phases: Phase 3, Phase 1, Phase 2 // Updated: Daily
Total Trials
10
Recruiting Now
10
Country
🇦🇺 Australia
Active Trials in Australia (10)
NCT07185997 Phase 3
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Enrollment
480 pts
Country
🇦🇺 Australia
ArriVent BioPharma, Inc.
View Trial → NCT06350097 Phase 3
Recruiting
Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer
Enrollment
582 pts
Country
🇦🇺 Australia
AstraZeneca
View Trial → NCT06060613 Phase 1, Phase 2
Recruiting
Safety and Efficacy of OBX-115 in Advanced Solid Tumors
Enrollment
208 pts
Country
🇦🇺 Australia
Obsidian Therapeutics, Inc.
View Trial → NCT06841055 Phase 2
Recruiting
Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment
Enrollment
60 pts
Country
🇦🇺 Australia
BioNTech SE
View Trial → NCT06712316 Phase 2, Phase 3
Recruiting
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
Enrollment
1,260 pts
Country
🇦🇺 Australia
BioNTech SE
View Trial → NCT06236438 Phase 2, Phase 3
Recruiting
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
Enrollment
840 pts
Country
🇦🇺 Australia
AbbVie
View Trial → NCT06312137 Phase 3
Recruiting
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
Enrollment
780 pts
Country
🇦🇺 Australia
Merck Sharp & Dohme LLC
View Trial → NCT04585750 Phase 1, Phase 2
Recruiting
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
Enrollment
300 pts
Country
🇦🇺 Australia
PMV Pharmaceuticals, Inc
View Trial → NCT05538130 Phase 1
Recruiting
A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors
Enrollment
124 pts
Country
🇦🇺 Australia
Pfizer
View Trial → NCT06765109 Phase 3
Recruiting
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
Enrollment
450 pts
Country
🇦🇺 Australia
Nuvalent Inc.
View Trial → Frequently Asked Questions
How many non small cell lung cancer clinical trials are active in Australia?
There are currently 10 active clinical trials for non small cell lung cancer with sites in Australia, of which 10 are actively recruiting patients.
How can I join a non small cell lung cancer clinical trial in Australia?
To join a non small cell lung cancer clinical trial in Australia, select a recruiting trial below and check the eligibility criteria. Contact the trial's principal investigator or the listed site in Australia directly. All trials listed here are sourced from ClinicalTrials.gov, the official U.S. registry of clinical studies.
What phases are non small cell lung cancer trials in Australia?
Active non small cell lung cancer trials in Australia span Phase 3, Phase 1, Phase 2, Phase 2, Phase 2, Phase 3, Phase 1. Phase I trials test safety, Phase II test efficacy, and Phase III compare against standard treatments in larger patient populations.
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: July 2026 · Data Methodology